Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LY3113593 in Hemodialysis Patients
NCT02604160Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Nov 2015
- Primary completion
- Jun 2016
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised trial in anemia of chronic kidney disease (CKD-A) comparing LY3113593 with Placebo (2 arms). Primary endpoint: Number of Participants With One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration. Started Nov 2015; status: completed.
02
Drugs
LY3113593
03
Conditions
anemia of chronic kidney disease (CKD-A)
Beyond the preview
Go deeper on NCT02604160.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02604160.